Vascular Endothelial Growth Factor Receptor-1
"Vascular Endothelial Growth Factor Receptor-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 180-kDa VEGF receptor found primarily in endothelial cells that is essential for vasculogenesis and vascular maintenance. It is also known as Flt-1 (fms-like tyrosine kinase receptor-1). A soluble, alternatively spliced isoform of the receptor may serve as a binding protein that regulates the availability of various ligands for VEGF receptor binding and signal transduction.
| Descriptor ID |
D040281
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.950.100 D12.776.543.750.630.750.100 D12.776.543.750.750.400.910.100
|
| Concept/Terms |
Vascular Endothelial Growth Factor Receptor-1- Vascular Endothelial Growth Factor Receptor-1
- Vascular Endothelial Growth Factor Receptor 1
- FLT1 Receptor Tyrosine Kinase
- VEGF Receptor flt-1 Protein
- VEGF Receptor flt 1 Protein
- VEGFR-1
- fms-Like Tyrosine Kinase
- Tyrosine Kinase, fms-Like
- Proto-Oncogene Protein flt
- Proto Oncogene Protein flt
- FLT1 RTK
- VEGF Receptor, FLT
- FLT VEGF Receptor
- Receptor, FLT VEGF
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor Receptor-1".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor Receptor-1".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor Receptor-1" by people in this website by year, and whether "Vascular Endothelial Growth Factor Receptor-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 4 | 2 | 6 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 2 | 4 |
| 2012 | 5 | 2 | 7 |
| 2013 | 6 | 2 | 8 |
| 2014 | 3 | 0 | 3 |
| 2015 | 3 | 3 | 6 |
| 2016 | 3 | 2 | 5 |
| 2017 | 2 | 2 | 4 |
| 2018 | 3 | 0 | 3 |
| 2020 | 4 | 0 | 4 |
| 2021 | 2 | 3 | 5 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor Receptor-1" by people in Profiles.
-
Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing. Am J Obstet Gynecol. 2024 Sep; 231(3):363.e1-363.e11.
-
Bioflavonoid luteolin prevents sFlt-1 release via HIF-1a inhibition in cultured human placenta. FASEB J. 2023 08; 37(8):e23078.
-
Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid. 2022 Dec; 1(12):EVIDoa2200161.
-
The additive role of angiogenic markers for women with confirmed preeclampsia. Am J Obstet Gynecol. 2023 05; 228(5):573.e1-573.e11.
-
Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. Pregnancy Hypertens. 2022 Aug; 29:108-115.
-
Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clin Chem. 2022 06 01; 68(6):771-781.
-
Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022 Mar; 27:42-50.
-
Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertens. 2021 Dec; 26:121-126.
-
Angiogenic factors and prediction for ischemic placental disease in future pregnancies. Pregnancy Hypertens. 2021 Aug; 25:12-17.
-
The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center. Pregnancy Hypertens. 2021 Aug; 25:7-11.